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Abstract
Botulinum neurotoxins (BoNTs) are extremely potent toxins that are capable of causing death or respiratory failure leading
to long-term intensive care. Treatment includes serotype-specific antitoxins, which must be administered early in the course
of the intoxication. Rapidly determining human exposure to BoNT is an important public health goal. In previous work, our
laboratory focused on developing Endopep-MS, a mass spectrometry-based endopeptidase method for detecting and
differentiating BoNT/A–G serotypes in buffer and BoNT/A, /B, /E, and /F in clinical samples. We have previously reported the
effectiveness of antibody-capture to purify and concentrate BoNTs from complex matrices, such as clinical samples. Because
some antibodies inhibit or neutralize the activity of BoNT, the choice of antibody with which to extract the toxin is critical. In
this work, we evaluated a panel of 16 anti-BoNT/A monoclonal antibodies (mAbs) for their ability to inhibit the in vitro
activity of BoNT/A1, /A2, and /A3 complex as well as the recombinant LC of A1. We also evaluated the same antibody panel
for the ability to extract BoNT/A1, /A2, and /A3. Among the mAbs, there were significant differences in extraction efficiency,
ability to extract BoNT/A subtypes, and inhibitory effect on BoNT catalytic activity. The mAbs binding the C-terminal portion
of the BoNT/A heavy chain had optimal properties for use in the Endopep-MS assay.
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Introduction
Botulinum neurotoxins (BoNTs) are protein toxins produced by
some species of the genus Clostridium, in particular, Clostridium
botulinum, C. butyricum, C. baratii, and C. argentinense. Intoxication with
one of the seven distinct serotypes of BoNT (A–G) causes botulism,
a disease that is contracted by ingestion of food containing the
toxin [1,2], colonization of the bacteria in the gastrointestinal tract
of infants or immunocompromised individuals, inhalation of the
toxin, or contact of the bacterium with a wound [1]. Due to its
high toxicity, availability, and ease of preparation, it is considered
a likely agent for bioterrorism [3]. Treatment of botulism involves
administration of therapeutic immunoglobulin product and is most
effective when administered within 24 hr of exposure [1].
However, the currently licensed antitoxins are serotype-specific,
mainly for BoNT/A and/or BoNT/B, while investigational
BoNT/E and BoNT/A–G are also available. Since these products
will not protect the patient if the botulism is caused by any of the
other serotypes, rapidly determining exposure to BoNT and
serotyping the toxin involved are critical to choose the right
antitoxin for treating the patient.
BoNTs are zinc metalloproteases which cleave and therefore
inactivate proteins which are necessary for acetylcholine release.
Each serotype of BoNT consists of a heavy chain (HC) of
approximately 100,000 daltons and a light chain (LC) of about
50,000 daltons. The heavy chain is responsible for both receptor
binding via its C-terminal (CT) binding domain [4,5] (HC) and
delivering the catalytic light chain (LC) to its target via its N-
terminal translocation domain (HN) [6]. The LC selectively cleaves
neuronal proteins required for acetylcholine release. Although the
LC accounts for the specific toxicity, it requires the heavy chain to
produce this toxic activity in vivo. BoNT/A, /C, and /E cleave
SNAP (synaptosomal-associated protein)-25 while BoNT/B, /D, /
F, /G and the closely related tetanus toxin all cleave synaptobrevin
2 (also called VAMP 2). Of the serotypes, only one, BoNT/C,
cleaves more than one specific protein. In addition to cleaving
SNAP-25, BoNT/C also cleaves syntaxin [2]. BoNTs are released
into the environment by clostridial species in a protein complex
consisting of the pure neurotoxin and a number of neurotox-
inassociated proteins (BoNT complex).
Previously, our laboratory reported on the development of an
assay for BoNT detection and serotype differentiation termed the
Endopep-MS method [7–12]. This method detects all 7 BoNT
serotypes and involves incubating BoNT with a peptide substrate
that mimics BoNT’s natural, in vivo target. Each BoNT cleaves its
peptide substrate in a specific location, and that location is
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different for each of the BoNT serotypes [2,7,9,12]. The reaction
mixture is then introduced into a mass spectrometer, which detects
and accurately reports the mass of any peptides within the
mixture. Detecting the peptide cleavage products corresponding to
their specific toxin-dependent location indicates the presence of a
particular BoNT serotype, A–G. If the peptide substrate either
remains intact, or is cleaved in a location other than the toxin-
specific site, then that BoNT serotype is not present at detectable
levels. Historically, mouse assays have been the most commonly
used method to detect BoNT [13], but as previous publications [7–
9,12] have demonstrated, the Endopep-MS method can detect
BoNT at levels comparable with or lower than levels detected with
mouse bioassays.
As previously reported, Endopep-MS is effective in identifying
BoNT/A, /B, /E, and /F in clinical samples. It uses an antibody
affinity concentration/purification step prior to reaction with the
substrate [9–12]. Polyclonal antibodies to BoNT/A, /B, /E, and /
F are available commercially and were found to be successful for
concentrating and purifying BoNT from a complex matrix.
However, because polyclonal antibodies consist of a heterogeneous
mixture of antibodies, they may recognize various portions of the
BoNT antigen molecule, each with different affinities. By contrast,
monoclonal antibodies (mAbs) recognize specific protein epitopes,
ensuring that they recognize a single antigenic site, and always
with the same affinity. Monoclonal antibodies have recently been
produced to BoNT/A [14–22] and we explored the use of these
high-affinity mAbs to improve the sample preparation portion of
the assay.
We also reported that binding polyclonal anti-BoNT/A could
interfere with the activity of the LC of BoNT/A as measured by
Endopep-MS [9] specifically, because Endopep-MS detects the
presence of BoNT by measuring the activity of the light chain.
Unfortunately, this can raise the BoNT-detection limit, depending
on where the antibodies bind to the toxin. We proposed, therefore,
the possibility that the assay might be improved by using selected
mAbs that do not bind the LC and thus, do not inhibit the
catalytic activity.
Another feature of BoNT/A is that it exhibits genetic and
amino acid variance within the toxin type, or serotype. As
currently defined, BoNT/A consists of /A1, /A2, /A3, and /A4
subtypes [23]. This variability among the BoNT/A subtypes
consists of 15% or less amino acid variance [23] and this variance
has been reported to affect binding of the toxin to anti-BoNT/A
mAbs [24]. For these reasons, it is important to be able to detect
all toxin subtypes because an outbreak of botulism may be
attributed to more than just the familiar BoNT/A1 subtype.
Our laboratory has already determined that the Endopep-MS
assay can be used to detect all currently known subtypes of BoNT/
A [12]. However, the sensitivity of the detection varies with
subtype. Our goal in this work is to evaluate a panel of mAbs for
their inhibitory and extraction abilities, thus optimizing assay
sensitivity with all BoNT/A subtypes. Unfortunately, BoNT/A4
only exists in conjunction with BoNT/bivalent B, and the /A4
component is considerably smaller than the B component. The
low concentration of BoNT/A4 makes it difficult to perform
multiple experiments, and therefore evaluating mAb extraction
and inhibition of BoNT/A4 will not be addressed in this work.
Here, we evaluate a panel of 16 monoclonal anti-BoNT/A mAbs
for their ability to inhibit the in vitro activity of the complex form of
BoNT/A1, /A2, and /A3 as well as the recombinantly produced
BoNT/A1 LC. We also evaluate the same antibody panel for the
ability to extract the complex form of BoNT/A1, /A2, and /A3.
The results indicate which mAbs have the optimal properties for
use in the Endopep-MS detection of BoNT/A.
Materials and Methods
Materials
Botulinum neurotoxin is very toxic and must be handled using
care and appropriate safety measures. All neurotoxins were
handled in a level 2 biosafety cabinet equipped with HEPA filters.
BoNT/A3, strain Loch Maree, crude culture supernatants were
produced from Clostridium botulinum after growth for 5 days at
35uC. After centrifugation of the culture, supernatant was
removed and filtered through 0.22-mm filters. The supernatant
was titered using a mouse intraperitoneal (i.p.) endpoint assay to
determine specific activity. The assay involves duplicate two-fold
dilutions ranging from 20 to 0.156 mouse LD50 (mLD50), based on
initial values of 56104 to 16105 mLD50. In addition, commer-
cially purified BoNT/A1 (strain Hall) and BoNT/A2 (strain FRI-
honey) complex toxins from Metabiologics (Madison, WI) were
used for comparative testing.
As described elsewhere [25], recombinant BoNT/A1 LC was
expressed and purified. Polyclonal anti-BoNT/A1 rabbit-specific
IgGs were provided by Metabiologics (Madison, WI) in 150 mM
potassium phosphate (pH 7.4). Monoclonal antibodies 3D12,
ING1, and ING2 were generated using display technologies from
human volunteers immunized with pentavalent BoNT toxoid
containing the BoNT/A1 subtype [17,22,26]. C25 was generated
from a mouse immunized with BoNT/A1 HC [17,21]. HuC25 is a
humanized version of C25, and AR1, AR2, AR4, CR1, and CR2
are mutants of HuC25 engineered to have higher affinity for
BoNT/A1 or better cross reactivity to the BoNT/A2 and /A3
subtypes [15,19]. B4 and 2A9 were generated from mice
transgenic for the human immunoglobulin locus that were
immunized with BoNT/A1 HC. RAZ1 is a mutant of 3D12
engineered to bind BoNT/A with higher affinity [19]. 2G11 is a
mutant of ING1 engineered to bind BoNT/A with higher affinity
[26]. 4A1 and 5A20 were generated using display technologies
from human volunteers immunized with pentavalent BoNT toxoid
containing the BoNT/A1 subtype [26]. 4A1.1 and 5A20.4 are
mutants of the human antibodies 4A1 and 5A20 engineered to
bind BoNT/A with higher affinity [26]. All of the above mAbs
were produced with human IgG1/kappa constant regions
recombinantly from Chinese Hamster Ovary cells and purified
to greater than 90% homogeneity by protein A affinity
chromatography. Purified IgG were buffer exchanged into
phosphate buffered saline (PBS) at a concentration of 1 mg/ml,
as previously described [16].
DynabeadsH Protein G were purchased from Invitrogen
(Carlsbad, CA) at 1.3 g/cm3 in phosphate buffered saline,
pH 7.4, containing 0.1% TweenH-20 and 0.02% sodium azide.
Except where indicated, all chemicals were from Sigma-Aldrich
(St. Louis, MO). Peptides were synthesized by Los Alamos
National Laboratory (Los Alamos, NM,) and are identical to
those reported previously [7–12]. Specifically, the peptide
substrate has the sequence biotin-KGSNRTRIDQGNQ-
RATRXLGGK-biotin and the internal standard peptide has the
sequence RATRXLGGK-biotin where A indicates a +7 mass
increase to a naturally-occurring alanine.
BoNT/A Inhibition Experiments
A 2-mL solution containing 30 ng of each titered IgG was added
to a 2-mL solution containing 100 mLD50 of BoNT/A1, /A2, /A3
or 230 pg recombinant LC BoNT/A1. The mixtures were
incubated for 1 hr at room temperature with no agitation. Then,
16 mL of a reaction mixture (0.05 M Hepes [pH 7.3], 25 mM
dithiothreitol, 20 mM ZnCl2, 1 mg/mL bovine serum albumin,
and 50 pmol/mL of peptide substrate) was added to the prior
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mixture. All samples then were incubated at 37uC for 4 h with no
agitation. All assays were performed in triplicate and results were
averaged.
BoNT A Extraction Experiments
The IgG was immobilized and crosslinked to the DynabeadsH
Protein G as described in previous publications [9–12]. An aliquot
of 20 mL of antibody-coated beads was mixed for 1 h with a 0.5-
mL solution containing 100 mLD50 of either BoNT/A1, /A2, or /
A3. The solution was prepared by spiking 2500 mLD50 of either
BoNT/A1, /A2, or /A3 into 12.5 mL of phosphate buffered
saline with 0.01% Tween (PBST) buffer. After mixing for 1 h with
constant agitation at room temperature, the beads were washed
twice in 1 mL each of PBST and then washed once in 100 mL of
water. The beads were reconstituted in a 20-mL solution
containing 0.05 M Hepes (pH 7.3), 25 mM dithiothreitol,
20 mM ZnCl2, 1 mg/mL bovine serum albumin, and 50 pmol/
mL of peptide substrate. All samples then were incubated at 37uC
for 4 h with no agitation. All assays were performed in triplicate
and results were averaged.
MS Detection
A master mix was created consisting of 9 parts matrix solution
(alpha-cyano-4-hydroxy cinnamic acid) at 5 mg/mL in 50%
acetonitrile, 0.1% trifluoroacetic acid (TFA), and 10 mM
ammonium phosphate) and 1 part internal standard peptide in
water at 5 mM. To 18 mL of this master mix, 2 mL of each reaction
supernatant were added. We pipeted 0.5 mL of this mixture onto
each spot of a 192-spot matrix-assisted laser desorption/ionization
(MALDI) plate (Applied Biosystems, Framingham, MA). Mass
spectra of each spot were obtained by scanning from 1100 to 3200
m/z in MS-positive ion reflector mode on an Applied Biosystems
4800 Proteomics Analyzer (Framingham, MA). The instrument
uses a nitrogen laser at 337 nm, and each spectrum is an average
of 2400 laser shots.
Results
Inhibition of BoNT/A Activity with Antibody Addition
The mAbs evaluated for their ability to inhibit substrate
cleavage by BoNT/A bind 6 different non-overlapping epitopes
on the BoNT/A HC, HN, LC-HN or LC with high affinity
(Table 1). Polyclonal antibodies were prepared using the entire
BoNT/A devoid of associated nontoxic proteins as immunogen
and thus likely contained antibodies binding to all BoNT/A
domains.
Inhibiting the enzymatic activity of BoNT/A upon addition of
antibodies depends upon the antigenic epitopes which the
antibody recognizes. Because BoNTs consist of two chains, with
one chain responsible for enzymatic activity (LC) and another
chain (HC) responsible for directing the enzymatically active light
chain to its target, antibodies reacting with the light chain of the
toxin may inhibit the toxin’s activity. Therefore, an inhibition
experiment was performed in which an equal amount of each
antibody was added to the BoNT/A Endopep-MS reaction. The
molar concentration of antibody in all cases exceeds the molar
concentration of toxin by at least 40 to 70 fold and exceeds the
dissociation equilibrium constant (KD) by at least 300 fold,
ensuring that essentially all of the LC is bound by antibody and
that antibody activity is evaluated separately from antibody
affinity. In this reaction, BoNT/A cleaves the peptide substrate
in a specific location, resulting in peptide cleavage products at
1197.7 and 1699.9 m/z. Greater levels of toxin or more active
toxin will produce more of these peptide cleavage products.
Because this experiment involves the use of equal levels of toxin
in all cases, the amount of cleavage product is therefore related to
the toxin’s activity rather than the amount of toxin. Because the
internal standard (ISTD) contains the same sequence as the C-
terminal (CT) cleavage product and the same amount of ISTD is
added to each sample, the ISTD can be used to measure the
amount of cleavage product and hence active toxin present in a
sample, compared with other samples. This inhibition experiment
was performed with a panel of 16 mAbs and one polyclonal
antibody preparation against BoNT/A1, /A2, and /A3 toxin
complexes and with recombinant LC of BoNT/A1. Table 2 lists
the peak area ratios of the native cleavage product over the ISTD
obtained from the reaction of these 4 toxins with the panel of 17
antibodies. An increase in peak area ratio indicates a more active
toxin. Figure 1 is a graph of percent inhibition of antibody as
calculated through the peak area ratios of each antibody compared
to the peak area ratio in the absence of antibodies.
The inhibition studies show that the catalytic activity of BoNT/
A1 toxin is inhibited to some degree in the presence of any
antibody (Table 2, Figure 1). The level of inhibition varies from
slight to almost complete depending on the particular antibody
used. For example, following mass spectrometric analysis, it is
clear that there is a CT cleavage product at 1197.7 m/z in the
reaction containing either the ING2 or CR2 antibodies (Figure 2).
Both reactions contain the same amount of ISTD at m/z 1204.7,
so by comparison of the size of the 1204.7 peaks with the size of
the 1197.7 peaks, we can determine that the amount of CT
cleavage product is much larger with the CR2 (2B) reaction than
with the ING2 (2A) reaction. The sum of the results for BoNT/A1
indicate that the polyclonal antibody and mAbs ING2, 2G11, and
polyclonal antibodies show between 95 and 100% inhibition, as
they yield reactions with the least CT cleavage product. Mabs
Table 1. A list of mAbs to BoNT/A with their epitopes and
affinities for BoNT/A1, A2, and A3 as measured by dissociation
rates (KDs).
Antibody BoNT/A epitope
IgG Affinity for BoNT by KD
(610212M21)
A1 A2 A3
C25 HCN-epitope 1 95.0 NM NM
HuC25 HCN-epitope 1 45.1 19,300 NM
AR1 HCN-epitope 1 12.4 .20,000 NM
AR2 HCN-epitope 1 6.8 20,100 NM
AR4 HCN-epitope 1 1.33 .20,000 NM
CR1 HCN-epitope 1 2.48 1730 NM
CR2 HCN-epitope 1 10.0 290 150
3D12 HCC epitope 2 60.7 152 NM
RAZ1 HCC epitope 2 1.48 3.69 4.65
2A9 HCC epitope 2 76.4 236.5 NM
B4 HCC epitope 3 95.9 NB NB
4A1.1 HN epitope 4 11.34 .1000 NM
ING1 LC-HN epitope 5 314.3 719.1 400
2G11 LC-HN epitope 5 25.1 40.4 18.0
ING2 LC epitope 5 9.57 7.42 NB
5A20.4 LC epitope 6 13.6 NB NB
NM indicates not measured and NB indicates that it does not bind.
doi:10.1371/journal.pone.0005355.t001
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ING1 and 2A9 show between 75 and 85% inhibition of BoNT/A1
compared with other antibodies.
These differences can be partially explained through knowledge of
the epitopes that these mAbs bind. The CR2 antibody binds an
epitope on BoNT/AHC, far from the catalytic LC (Table 1) [27]. By
contrast, the ING2 antibody binds an epitope on the LC (Table 1)
[27] and inhibits the LC catalytic activity. Since the ING2 mAb is
bound to the catalytically active portion of the toxin, the toxin is not
as free to access its peptide substrate for cleavage. Note that not all of
the LC binding mAbs are strongly inhibitory (e.g. 5A20.4 as
evidenced in Table 2), indicating that the precise LC epitope bound
determines whether there is catalytic inhibition or not.
ING1 and 2G11 are clonally related mAbs that bind identical
epitopes requiring the presence of both the LC and the HN toxin
domains [27]. Since these mAbs do not have detectable binding to
LC [27], we hypothesize that the mAbs hinder dissociation of the
LC from the heavy chain, an event which many believe enhances
catalysis. Both antibodies inhibit the activity of BoNT/A1, with
the higher affinity antibody showing the greater inhibition
(Table 2). The mechanism by which 2A9, a BoNT/A1 HC
binder, inhibits the reaction is not known. The polyclonal antibody
is directed against many epitopes and it appears that some of these
epitopes cause binding of the polyclonal antibody to regions of the
BoNT/A1 molecule that also interfere with its ability to interact
with its peptide substrate.
Figure 1 and Table 2 also depict the results of the reaction of
these same antibodies with recombinant BoNT/A1 light chain
alone. These data are consistent with that of BoNT/A1 complex,
with a few exceptions: ING2, 2A9, and 5A20.4. All three of these
antibodies have some inhibitory effect against BoNT/A1 complex,
but do not appear to be very inhibitory against the light chain of
BoNT/A1 alone.
The lack of LC inhibition by ING2 and 5A20.4 is difficult to
explain, as both of these mAbs bind yeast displayed and
recombinant BoNT/A LC [27, unpublished]. The translocation
domain contains a belt-like region that wraps around the LC,
holding it against the HN in a way that prevents catalytic interaction
with substrate [28]. One possible explanation is that in the intact
neurotoxin these mAbs at least partially inhibit catalysis by
preventing LC dissociation from the holotoxin, rather than by
blocking substrate binding. Alternatively, the conformation of the
recombinant light chain may be different from that in the BoNT/
A1 complex in the reaction mixture such that ING2 and 5A20.4
cannot bind the recombinant light chain with as high affinity as the
light chain within the BoNT/A1 complex. Monoclonal antibody
2A9 shows substantial inhibition of BoNT/A1, but not /A1 LC.
This mAb binds to an undetermined epitope on the HC portion of
the toxin. The HC portion is not present in the recombinant light
chain, so this antibody cannot bind the toxin in order to inhibit it.
The BoNT/A2 protein differs from BoNT/A1 by 10% at the
amino acid level. Because it is important to understand whether
these genetic differences result in extraction or inhibition
differences with various antibodies, the above panel of antibodies
Figure 1. A graph indicating the % of inhibition in activity of BoNT/A1 or /A1 light chain following neutralization with the antibody
panel. The sample with no antibodies had no inhibition of activity, so the % of inhibition in activity is calculated by dividing the peak area ratio of
the peptide cleavage product over the internal standard peptide of the individual antibody by the peak area ratio of the sample with no antibodies.
doi:10.1371/journal.pone.0005355.g001
Table 2. Peak area ratios of the peptide cleavage product
over the internal standard peptide obtained from the
Endopep-MS reaction of BoNT/A with its peptide substrate in
the presence of the antibody panel.
Antibody BoNT A1 BoNT A1 Light Chain BoNT A2 BoNT A3
Polyclonal 0.02 0.29 0.01 0.82
2G11 0.12 0.16 0.15 0.98
ING2 0.28 1.02 0.05 3.31
ING1 1.12 0.24 1.79 2.96
2A9 1.25 0.92 1.18 1.94
5A20.4 1.51 1.22 1.43 1.99
B4 1.98 0.41 1.09 2.17
AR4 2.07 0.63 1.51 2.13
AR2 2.12 0.66 1.52 2.28
CR1 2.36 0.68 1.23 2.73
4A1.1 2.42 0.39 1.28 2.64
AR1 2.46 0.53 1.68 3.02
RAZ1 2.71 0.71 0.97 2.49
HuC25 2.85 0.83 1.84 3.14
3D12 3.83 0.78 1.78 3.36
C25 4.45 0.78 2.54 3.51
CR2 5.67 0.74 1.64 3.92
none 6.19 1.25 2.75 4.48
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was also examined for inhibition of BoNT/A2. The data in Table 2
show that, despite genetic differences, most of the results for
inhibition of BoNT/A2 are similar to that of BoNT/A1 complex,
with the exception of the ING1 and CR2 antibodies. ING1 has a
greater inhibitory effect against BoNT/A1 than it does against
BoNT/A2. This may result from the 2.3-fold lower affinity for
BoNT/A2.
By contrast, mAb 2G11, which was engineered for better cross-
reactivity than ING1, has a much better affinity for both BoNT/A1
and /A2 (Table 1) and shows a high level of inhibition against both
toxins. CR2, which was also engineered for better cross-reactivity,
shows greater inhibition against BoNT/A2 than BoNT/A1. This
contrasts with mAbs AR1-4, which show greater inhibition against
BoNT/A1 than BoNT/A2 and were engineered for high affinity
binding to BoNT/A1, not for better cross-reactivity to /A2 and /A3.
BoNT/A3 differs from BoNT/A1 by 15% at the amino acid
level, and from BoNT/A2 by 6.3% [23], so we wanted to examine
whether this panel of antibodies neutralized BoNT/A3 as well.
The results are comparable to that of BoNT/A1 complex, with the
exceptions of the ING1, ING2, and 2G11 antibodies (Table 2).
Again, these antibodies are not as inhibitory toward BoNT/A3 as
they are toward BoNT/A1 complex. ING2 binds BoNT/A1 and /
A2 with low picomolar efficiency, but it does not bind /A3, and
thus it does not inhibit the interaction of toxin with substrate. As
mentioned above, 2G11 is a version of ING1 that was engineered
for greater cross-reactivity among BoNT/A subtypes, and the
success with this is seen in both the increased binding affinity
(Table 1) and inhibition against both BoNT/A2 and /A3
compared with ING1.
BoNT/A extraction efficiency
After determining which antibodies were more inhibitory
toward the catalytic activity of BoNT/A1, /A2, and /A3, we
wanted to examine the ability of the panel of antibodies in our
assay to extract BoNT/A1, /A2, and /A3 in the Endopep-MS
assay. All antibodies were used to extract the same level
(100 mLD50) of BoNT/A from a buffer solution. Following
extraction, the toxins on the beads were added to identical
reaction mixtures containing peptide substrate. Upon mass
spectrometric analysis, it is apparent (see Figure 3) that the CR2
(3A), ING2 (3B), and B4 (3C) antibody-extracted samples contain
the internal standard at m/z 1204.7, but that only the CR2 and
ING2 antibody-extracted samples contain C-terminal cleavage
product at m/z 1197.7. Comparing the CT products with ISTDs
shows that the CR2 antibody-extracted sample contains more C-
terminal cleavage product than the B4 or ING2 antibody-
extracted samples. Since all samples contain the same amount of
internal standard, the generation of a higher level of cleavage
product indicates a greater level of toxin, a greater activity of
toxin, or possibly both.
Table 3 contains the peak area ratios of the cleavage product over
the ISTD for 16 BoNT/A mAbs and one polyclonal antibody
product used to extract either BoNT/A1, /A2, or /A3. mAbs
ING1, ING2, 2A9, 2G11 and B4 yielded minimal cleavage product.
Because the inhibitory experiments showed that the ING1, ING2,
2A9, and 2G11 antibodies inhibited the activity of BoNT/A1
complex, the decreased cleavage products after extraction with
these antibodies are likely due to inhibition of activity rather than
poor extraction efficiency. However, the inhibitory experiments
determined that the decrease in BoNT/A1 activity in the presence
of mAb B4 was equivalent to all other noninhibitory antibodies with
the exception of CR2. Therefore, the decrease in cleavage product
must be due to a decrease in the amount of toxin that was extracted
rather than a decrease in the toxin’s activity due to inhibition by the
antibody. This poor extraction efficiency cannot be attributed to the
binding affinity of B4 for BoNT/A1 (95.9 pM) but rather may
reflect either poor coupling of the mAb to the beads or inactivation
of the mAb upon coupling.
As with the inhibition studies, we also wanted to look at possible
extraction efficiency differences due to genetic differences among
the three BoNT/A subtypes. Only a few antibodies that had good
extraction efficiency for BoNT/A1 also had good extraction
efficiency for BoNT/A2 and BoNT/A3. These include CR1,
CR2, 3D12, and RAZ1. Not surprisingly, the ability to extract the
BoNT/A2 and BoNT/A3 subtypes was correlated with affinity.
mAbs that did not bind these subtypes (4A1.1 and 5A20.4)
exhibited no extraction. mAbs that bound BoNT/A2 and BoNT/
A3 poorly (KD.200 nM, C25, AR1, AR2, and AR4) showed
significantly less extraction than clonally related mAbs binding the
same epitope with affinities less than 100 pM (CR1 and CR2).
However the correlation of extraction efficiency with binding
constant was not linear. At KD,100 pM, there were not
Figure 2. Mass spectra of the Endopep-MS BoNT/A1 reaction with either ING2 (2A) or CR2 (2B) antibodies. The peptide cleavage
product indicating BoNT/A1 is present in both cases at m/z 1197.7 and the internal standard is present at m/z 1204.7.
doi:10.1371/journal.pone.0005355.g002
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significant differences in the extraction efficiencies of clonally
related mAbs binding the same epitope (compare C25 vs AR4 for
BoNT/A1 and 3D12 and RAZ1 for BoNT/A1, BoNT/A2, or
BoNT/A3). This absence of effect likely reflects the binding rate
constant. All of these mAbs have fast association rate constants
(kon) and the KD differences are largely due to differences in the
dissociation rate constants (koff) [19]. However, the mAbs with the
fastest koff would remain associated with toxin with a half life of
greater than 2 hours, thus not allowing time for the toxin to escape
the bead capture before incubation with substrate.
Discussion
The Endopep-MS assay relies upon antibody extraction of
BoNT/A from a clinical or food sample as a sample preparation
step prior to analysis for the toxin, so using the correct antibodies is a
critical component of the assay. Because the assay is activity-based
such that the toxin is detected through the enzymatic cleavage of
target proteins, it is critical to include in the extraction step
antibodies that do not hinder the activity of the toxin. Therefore, it
is important to perform experiments to determine the inhibition
ability of an antibody against BoNT/A prior to choosing an
antibody for extracting BoNT/A. For the assay to be optimal, we
would also like to choose an antibody that demonstrates a strong
extraction efficiency for BoNT/A. Finally, the antibodies must have
good extraction efficiencies for all known BoNT/A, which currently
includes the BoNT/A1, /A2, /A3, and /A4 subtypes.
We therefore tested a panel of antibodies against BoNT/A1, /
A2, and /A3 and examined both their inhibitory ability as well as
their extraction efficiency. Antibodies that gave good results with
all three toxin types were CR1, CR2, 3D12, and RAZ1. CR1 and
CR2 bind the same C25 epitope, and the remaining two
antibodies, 3D12 and RAZ1 bind a different non-overlapping
epitope. It is known that using multiple antibodies that bind non-
overlapping epitopes increases the effective affinity for the toxin by
as much as 200-fold over the affinity of the individual antibodies
[17]. Using multiple antibodies having different epitopes not only
increases overall binding affinity, which is important for toxin
Figure 3. Mass spectra of the Endopep-MS botulinum neurotoxin A reaction after extraction of the toxin with either CR2 (3A), ING2
(3B), or B4 (3C) antibodies. The peptide cleavage product indicating the presence of BoNT/A is present in both cases at m/z 1197.7 and the
internal standard is present at m/z 1204.7.
doi:10.1371/journal.pone.0005355.g003
Table 3. Peak area ratios of the peptide cleavage product
over the internal standard peptide obtained from the
Endopep-MS reaction of BoNT A after its extraction by the
antibody panel.
Antibody BoNT A1 BoNT A2 BoNT A3
Polyclonal 0.31 0.15 0.24
2G11 0.02 0.06 0
ING2 0.02 0.09 0.06
ING1 0.12 0.21 0.12
2A9 0.02 0.03 0
AR2 1.03 0.27 0.12
CR1 1.1 0.75 1.02
RAZ1 1.07 1.17 0.66
AR4 1.31 0.39 0.42
5A20.4 0.32 0.03 0
AR1 0.88 0.15 0.12
B4 0 0 0
HuC25 1.09 0.33 0.36
4A1.1 1.03 0.03 0.3
C25 1.52 0.33 0.42
3D12 0.99 1.11 1.02
CR2 1.07 0.96 1.08
Three different forms of BoNT A were used, and they include A1, A2, and A3.
doi:10.1371/journal.pone.0005355.t003
Evaluating Anti-BoNT/A
PLoS ONE | www.plosone.org 6 April 2009 | Volume 4 | Issue 4 | e5355
extraction, but it also offers a unique opportunity to design a
mixture of antibodies that bind a variety of epitopes, including
regions that are conserved across the BoNT/A subtypes. This is
important because we need the antibodies to be as inclusive as
possible. Although only four subtypes of BoNT/A are currently
known, it is possible that in the future that other BoNT subtypes
may be discovered. While a new BoNT subtype may have an
amino acid mutation in one epitope that prevents its extraction
from a sample matrix by an antibody, the probability of mutation
in two different epitopes is more remote. Therefore, using multiple
antibodies against multiple epitopes is preferred for this assay.
From these studies, it appears that antibodies from two distinct
epitopes that bind BoNT/A1, /A2, and /A3 with high affinity but
do not inhibit the activity of the toxin would be the optimal
antibodies to use in these assays. BoNT/A HC epitopes appear to
interfere with toxin activity less than LC or HN epitopes, so we
focused on HC antibodies. The HC epitopes showing the best toxin
extraction efficiencies were the C25 and 3D12 epitopes.
Examining the calculated dissociation rate (KD) for BoNT/A1
and /A2 with the clonally related antibodies from these epitopes
shows that CR2 has a substantially lower (better) KD, or
dissociation equilibrium constant, for BoNT/A2 than CR1, and
equivalent low KDs for BoNT/A1 are seen for both antibodies. In
addition, CR2 is known to bind BoNT/A3 with a high affinity of
150 pM. The RAZ1 antibody shows a 40-fold increase in affinity
for both BoNT/A1 and /A2 compared to the parental 3D12, and
this antibody shows the highest overall affinity against all three
BoNT/A subtypes with KDs ranging from 1.48–4.65 pM. Because
of these findings, we have opted to use a mixture of RAZ1 and
CR2 as the antibodies to extract BoNT/A1, /A2, and /A3 from
sample matrices prior to analysis with the Endopep-MS method.
Because BoNT/A4 is produced in low levels, it was not feasible
to test the entire antibody panel against BoNT/A4. However,
RAZ1/CR2, the chosen antibody mixture, was tested against
BoNT/A4 and has been found to efficiently extract BoNT/A4 for
detection by Endopep-MS [12]. Thus, we have been able to show
the RAZ1/CR2 antibody combination is effective at extracting
and concentrating all known subtypes of BoNT/A prior to analysis
by Endopep-MS.
In addition to determining the best antibodies for sample
preparation prior to Endopep-MS, this work has determined in
vitro inhibition abilities of a panel of antibodies against BoNT/A1,
/A2, and /A3. Many antibodies show similar results with BoNT/
A1, /A2, and /A3, but in some cases they differ, indicating
differing toxin extraction efficiencies due to differing binding
affinities or inhibition of toxin activity. These findings indicate that
antibody choice is crucial to the ability of these types of assays to
sensitively detect a diverse range of BoNT/A toxin subtypes,
which is a critical first step to providing proper treatment in a
timely manner. In addition, these antibody characterizations have
the potential to assist with mechanistic studies of BoNT/A, which
is important for studying alternative treatments for botulism.
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